透明细胞肾细胞癌液体活检中细胞外囊泡来源mRNA生物标志物鉴定的进展
本研究旨在提出细胞外囊泡(EV)来源mRNA作为检测透明细胞肾细胞癌(ccRCC)存在的潜在诊断生物标志物。研究从有限数量的ccRCC患者中收集尿液、血浆、癌旁正常组织和肿瘤组织,分离EV并提取mRNA,使用NanoString nCounter技术对匹配样本中的mRNA转录本进行计数。结果评估了770个与癌症进展和转移相关的mRNA转录本,发现四种EV来源mRNA转录本(ALOX5、RBL2、VEGFA、TLK2)对尿液和肿瘤组织样本具有特异性。结论认为鉴定出四种候选RCC特异性尿液EV生物标志物,但由于缺乏真正的阴性对照和尿液收集技术限制,需要进一步复核验证。
要点
- 评估了770个与癌症进展和转移相关的mRNA转录本。
- 四种EV来源mRNA(ALOX5、RBL2、VEGFA、TLK2)对尿液和肿瘤组织样本具有特异性。
- 鉴定出四种候选RCC特异性尿液EV生物标志物,但需进一步复核验证。
核心结论
- 鉴定出四种候选RCC特异性尿液EV生物标志物,但由于缺乏真正的阴性对照和尿液收集技术,需要进一步复核验证。
- 本研究证明了在液体活检患者样本中定义疾病特异性EV生物标志物的前景。
研究设计与样本
- 从有限数量的ccRCC患者中收集尿液、血浆、癌旁正常组织和肿瘤组织样本。
- 对每个样本进行EV分离,随后从分离的EV中提取mRNA。
- 使用NanoString nCounter技术对匹配的血浆、尿液、肿瘤组织和癌旁正常组织样本中存在的mRNA转录本进行计数。
主要发现
- 评估了770个与癌症进展和转移过程相关的mRNA转录本。
- 四种EV来源mRNA转录本(ALOX5、RBL2、VEGFA、TLK2)被发现对尿液和肿瘤组织样本具有特异性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 缺乏真正的阴性对照。
- 尿液收集技术存在限制。
- 需要进一步复核验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To propose EV-derived mRNA as a potential diagnostic biomarker detecting the presence of clear cell renal cell carcinoma (ccRCC). There is currently no kidney cancer specific screening or diagnostic technology. Therefore, one-third of kidney cancer diagnoses occur after the cancer has metastasized and is past curative measures MATERIALS AND METHODS: Urine, plasma, normal tumor adjacent tissue, and tumor tissue was collected from a limited population of ccRCC patients. Extracellular vesicle (EV) isolation was performed on each sample, followed by mRNA extraction from isolated EVs. NanoString nCounter technology was utilized to count the mRNA transcripts present in matched plasma, urine, tumor tissue, and normal tumor adjacent tissue samples. RESULTS: 770 mRNA transcripts related to gene's affecting cancer's progression and metastasis processes were evaluated. Four EV derived mRNA transcripts (ALOX5, RBL2, VEGFA, TLK2) were found specific to urine and tumor tissue samples. CONCLUSION: Four candidate RCC-specific urine EV biomarkers were identified. However, due to the lack of a true negative control and urine collection techniques, further re-examination is necessary for validation. This study demonstrates the promise of defining disease-specific EV biomarkers in liquid biopsy patient samples.
引用
- Kuczler MD, Zieren RC, Dong L, et al. Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas. Urology. 2021. PMID: 34793840. doi:10.1016/j.urology.2021.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。